HomeHOW WE ADD VALUE

HOW WE ADD VALUE

VestBio Capital

World Class Biotech Companies

Companies from the World’s Best Life Sciences Hubs: Boston & USA, UK, Switzerland

…with Excellent Management teams (i.e., Pfizer Ex-president, CEO with more than 7 IPOs with an average of x12,…)

…and Exit in 4 years as maximum. Nasdaq Pre-IPOs preferred (3 years as maximum to exit)

Clinical Stage Therapeutic Drug Development Companies

Outstanding Teams:

Experienced leadership with a track record of success

Exit Engineered:

Relatively short timeline to value inflection. Indications and disease areas that have large-pharma partnership interest.

Pipeline:

Diversified with multiple “shots on goal” with hints of human efficacy or data in patients preferred, In large addressable Market

Building truly differentiated Science with global impact:

Significant unmet medical needs at an Agnostic Stage (preclinical - commercialization), with a clear and capital-efficient regulatory pathway. Strong and established IP position